Stock info Sartorius | Filter  Basic-Info

Sartorius

The past year was a profitable year for Sartorius investors

Over the past year the company' stock lost around 0 percent. Over the past 5 years Sartorius' stock rose at around 826 percent in value. Sartorius's revenues between 2011 and 2015 were very volatile through the time and moved between 845,71 million euros and 1,11 billion euros. During 2011 and 2015 Sartorius's net results were very volatile and fluctuated between 52,8 million euros and 117,4 million euros.

Sartorius primarily operates in the biotech sector. The global biotech companies gained over the past 10 years on average 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

Sartorius paid out dividends in the past 5 years. Sartorius's dividend return over the period 2011 - 2015 was around 5,3 percent per year.

Healthy financed: not so much debt Sartorius

At the end of 2015 the German company's balance sheet was worth 1,44 billion euros. The total debt was around 919,51 million euros. This is 63,98 percent of the total balance sheet. The German company's price/earnings-ratio was 18. So the market valued the stock at 18 times the 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the German stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the biotech company equaled around 5,31 billion euros. At the end of 2015 the German company had around 17,05 million stocks listed.

All of Sartorius's annual reports are stored here. More information about Sartorius can be found it's website. .